Search results
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
Events
FIBRIPHEN™ LRT
Clotting method for quantitative determination of fibrinogen (Clauss method)
FII Inhibitor Plasma (1) mild (1-10 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FIX Inhibitor Plasma (1) mild (1-10 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FIX Inhibitor Plasma (1) mild (1-10 BU/ml), lyophilized
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FIXa Calibrator
Lyophilized plasma for the calibration of factor IXa measurements using the chromogenic assays and especially BIOPHEN Factor IXa assay (ref. 221812).
FIXa Controls (ultra low)
Factor IXa controls are intended for the quality control of activated factor IX (FIXa) chromogenic measurements (approx. 1.3 mlU/mL), using BIOPHEN® Factor IXa assay (ref. 221812).
FIXa Controls (ultra low)
Factor IXa controls are intended for the quality control of activated factor IX (FIXa) chromogenic measurements (approx. 0.2 mIU/mL), using BIOPHEN Factor IXa assay (ref. 221812).
FPA Control - ELISA
Quality control of FPA assay (RK016A).